Éric Fortin

ORCID: 0000-0003-0457-5306
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ocular Diseases and Behçet’s Syndrome
  • Retinal and Optic Conditions
  • Systemic Lupus Erythematosus Research
  • Vasculitis and related conditions
  • Cytomegalovirus and herpesvirus research
  • HIV Research and Treatment
  • Immune Response and Inflammation
  • Syphilis Diagnosis and Treatment
  • Inflammasome and immune disorders
  • Retinal Diseases and Treatments
  • Glaucoma and retinal disorders
  • Yersinia bacterium, plague, ectoparasites research
  • Occupational Health and Safety Research
  • Dermatology and Skin Diseases
  • Aging and Gerontology Research
  • Pharmaceutical studies and practices
  • Assisted Reproductive Technology and Twin Pregnancy
  • Interprofessional Education and Collaboration
  • Inflammatory Bowel Disease
  • Cerebral Venous Sinus Thrombosis
  • Cultural Competency in Health Care
  • Medicine and Dermatology Studies History
  • Palliative Care and End-of-Life Issues
  • Ocular Oncology and Treatments
  • Health and Wellbeing Research

Université de Sherbrooke
2025

Université de Montréal
1993-2023

Hôpital Maisonneuve-Rosemont
2009-2023

St. Mary's College
2018

Saint Mary's College of California
2009

National Eye Institute
1998-2003

National Cancer Institute
1998-1999

National Institutes of Health
1998-1999

Mount Sinai Hospital
1998

University Hospital Ayr
1998

Andrew D. Dick James T. Rosenbaum Hassan Al-Dhibi Rubens Belfort Antoine P. Brézin and 95 more Soon‐Phaik Chee Janet L. Davis Athimalaipet V Ramanan Koh‐Hei Sonoda Ester Carreño Heloísa Nascimento S. Ben Salah Sherveen Salek Jay Siak Laura R Steeples Massimo Accorinti Nisha R. Acharya Alfredo Adán Rupesh Agrawal Nurullah Akkoç Saed Al Ghamdi Turki Al Ghamdi Anood Al Saati Nasser Alsabaani Mohamed Al-Shamarani Artur Bachta Talin Barisani‐Asenbauer Nicholas A. V. Beare Fernanda Belga Ottoni Porto Ricardo Blanco Anita Chan Sook Yee Vinod Chandran Christophe Chiquet Hiok Hee Chng Andrius Cimbalas Luca Cimino Miguel Cordero‐Coma C. Blanco Cristóbal Miguel Cuevas João Eurico da Fonseca Joke de Boer Alejandra de‐la‐Torre Ilse De Schryver Larissa Derzko-Dzulynsky David Díaz‐Valle Claudia Eugenia Duran Merino Andrea Facskó Luís Fígueira Alejandro Fonollosa Éric Fortin Richard Gale Mauro Galeazzi Sandra García José María García Ruiz de Morales Nataša Gašperšič Debra A. Goldstein Marta Guedes Yan Guex‐Crosier Ahmet Gül Rola N. Hamam Muhammad Haroon Kenichi Hasegawa Arnd Heiligenhaus Claire Hooper Yih‐Shiou Hwang De‐Kuang Hwang Xavier Juanola Toshikatsu Kaburaki Sibel Kadayıfçılar John H. Kempen Takeshi Kezuka Amin Kherani Maarja Kirsimäe Kaisu Kotaniemi Aleksandra Kraut Agnieszka Kubicka‐Trząska Lucia Kuffová Susan Lightman Lyndell L. Lim Wee Kiak Lim Peter McCluskey Mairide McGuire Pierfrancesco Mirabelli Elisabetta Miserocchi Marta Misiuk‐Hojło Cristina Muccioli Santiago León Atehortúa Muñoz Conor C. Murphy Philip I. Murray Zoltán Zsolt Nagy Kenichi Namba Piergiorgio Neri Quan Dong Nguyen Donncha O’Gradaigh Mohammed A. Omair Kati Otsa Yılmaz Özyazgan Franco Pablo Maria Pia Paroli Uwe Pleyer

An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in era biologics.The availability biologic agents human eye disease has altered practice patterns management uveitis. Current guidelines are insufficient assure optimal use noncorticosteroid systemic immunomodulatory agents.An international expert steering committee comprising 9 specialists (including both ophthalmologists and rheumatologists)...

10.1016/j.ophtha.2017.11.017 article EN cc-by-nc-nd Ophthalmology 2018-01-06

To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis.Phase 3, open-label, multicenter clinical trial extension (VISUAL III).Adults meeting treatment failure (TF) criteria who completed VISUAL I II (phase randomized, double-masked, placebo-controlled) without TF.Patients received 40 mg every other week. Interim follow-up data were described from III weeks 0 through 78.Disease quiescence, steroid-free active inflammatory...

10.1016/j.ophtha.2017.12.039 article EN cc-by-nc-nd Ophthalmology 2018-02-09

To evaluate the safety and potential therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in treatment patients with severe, sight-threatening, intermediate posterior noninfectious uveitis, a nonrandomized, open-label, pilot study was performed. Patients uveitis were treated minimum 20 mg prednisone, cyclosporine, antimetabolites, or any combination these agents eligible. weaned off their systemic immunosuppressive according to standardized schedule, while ultimately...

10.1073/pnas.96.13.7462 article EN Proceedings of the National Academy of Sciences 1999-06-22

PurposeTo evaluate long-term efficacy and safety of extended treatment with adalimumab in patients noninfectious intermediate, posterior, or panuveitis.DesignOpen-label, multicenter, phase 3 extension study (VISUAL III).ParticipantsAdults who had completed a randomized, placebo-controlled parent trial I II) without failure (inactive uveitis) discontinued the after meeting criteria (active uveitis).MethodsPatients received subcutaneous 40 mg every other week. Data were collected for ≤ 362...

10.1016/j.ophtha.2020.10.036 article EN cc-by-nc-nd Ophthalmology 2020-11-03

Abstract Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by continuous colonic inflammation. In Canada, ~160,000 people suffer from its symptoms, such as diarrhea, blood in the stool and abdominal pain, which can highly impact their quality of life. For moderate to severe forms disease, molecular targeted therapies (MTT) are used control symptoms achieve remission. There large variability treatment response MTT. Indeed, ~20-50% MTT users don’t improve...

10.1093/jcag/gwae059.170 article EN cc-by Journal of the Canadian Association of Gastroenterology 2025-02-01

To evaluate the efficacy and safety of trabeculotomy in treatment pediatric uveitic glaucoma (UG).We retrospectively reviewed all cases that underwent for UG at our center between 2008 2014. Up to 2 trabeculotomies per eye were performed patients with medically controlled uveitis. Surgical success was defined as final intraocular pressure <22 mm Hg ≥6 after 1 or trabeculotomies, without medications. Kaplan-Meier survival analyses done.A total 33 28 eyes 22 patients. Diagnoses included...

10.1097/ijg.0000000000000516 article EN Journal of Glaucoma 2016-08-23

To develop Canadian recommendations for the screening, monitoring, and treatment of uveitis associated with juvenile idiopathic arthritis (JIA). Recommendations were developed using Grading Assessment, Development, Evaluation (GRADE)-ADOLOPMENT approach. A working group 14 pediatric rheumatologists, 6 ophthalmologists, 2 methodologists, 3 caregiver/patient representatives reviewed recent American College Rheumatology (ACR)/Arthritis Foundation (AF) worked in pairs to evidence-to-decision...

10.3899/jrheum.220261 article EN The Journal of Rheumatology 2022-10-15

Purpose: To assess efficacy of adalimumab versus placebo in patients with active or inactive noninfectious intermediate, posterior, panuveitis across different etiologies.Methods: VISUAL I (V–I) and II (V–II) clinical trials included adults uveitis, respectively, randomized to receive placebo. In a post hoc subgroup analysis, time treatment failure (TTF) starting at week 6 2 was analyzed using the Kaplan–Meier method. Hazard ratios (HR) for TTF 95% CI were calculated Cox proportional hazards...

10.1080/09273948.2020.1757123 article EN cc-by Ocular Immunology and Inflammation 2020-05-29

Lens-associated uveitis (LAU), a severe inflammatory eye disease, is thought to be mediated by autoimmunity against lens crystallins. Previously described animal models for this disease are antibody-mediated, since no cellular response self crystallins could induced in experimental animals. Here, we describe new model LAU, which lymphocytes from knockout mice deficient alphaB-crystallin sensitized the deleted protein and induce ocular inflammation when adoptively transferred into wild type...

10.1046/j.1365-2249.2003.02218.x article EN Clinical & Experimental Immunology 2003-07-17

De façon générale, les enquêtes statistiques disponibles au Québec examinent conditions de travail indépendamment des caractéristiques travailleurs aux plans la santé et lésions professionnelles. L’Étude québécoise travail, d’emploi sécurité du (EQCOTESST) vise à corriger cette lacune. La première phase ce projet d’enquête quinquennale auprès 5 000 est prévue pour 2007. À l’aide ces données, il sera possible d’analyser liens existants entre un ensemble l’état risques d’accidents travail.

10.3406/oss.2006.1134 article FR Santé Société et Solidarité 2006-01-01
Coming Soon ...